Shilpa Medicare is currently trading at Rs. 567.85, up by 17.05 points or 3.10% from its previous closing of Rs. 550.80 on the BSE.
The scrip opened at Rs. 554.00 and has touched a high and low of Rs. 580.00 and Rs. 545.90 respectively. So far 70716 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 692.45 on 11-Aug-2020 and a 52 week low of Rs. 317.05 on 19-Mar-2021.
Last one week high and low of the scrip stood at Rs. 580.00 and Rs. 521.85 respectively. The current market cap of the company is Rs. 4639.70 crore.
The promoters holding in the company stood at 53.25%, while Institutions and Non-Institutions held 20.64% and 26.12% respectively.
Shilpa Medicare has received an in-principle approval from Defence Research & Development Organisation (DRDO) to manufacture and sale of 2-Deoxy-D-Glucose (2DG). 2DG has been given emergency approval by the Drug Controller General of India (DCGI) for COVID-19 patients in the country. Shilpa Medicare is only the second company in India to have entered into similar arrangement with DRDO.
Shilpa has been continuously striving to contribute towards the fight against COVID-19 and this is yet another step by Shilpa after its recently announced arrangement for manufacture and supply of Sputnik V vaccine.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1520.55 |
Dr. Reddys Lab | 6217.15 |
Cipla | 1405.40 |
Zydus Lifesciences | 953.50 |
Lupin | 1589.10 |
View more.. |